title: Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
authors: Urology Nephrology Research Center (UNRC), Labbafi Nejad Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran. Poorreza@hotmail.com
authors: F
authors: F
authors: Poorrezagholi
authors: B
authors: B
authors: Einollahi
authors: A
authors: A
authors: Firoozan
authors: M
authors: M
authors: Nafar
authors: H
authors: H
authors: Yadegari
authors: S M M H
authors: SM
authors: Moghaddam
authors: N
authors: N
authors: Simforoosh
authors: A
authors: A
authors: Basiri
authors: S
authors: S
authors: Farhangi
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012107:Research Design; D016037:Single-Blind Method
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab